Prior to joining Chimerix in 2007, Dr. Lanier contributed to the HIV and cancer programs at Burroughs Wellcome, GlaxoWellcome and GlaxoSmithkline where he supervised a clinical virology/immunology laboratory, led teams for drug discovery and was instrumental in clinical development of HIV antivirals including 3 successful NDAs. Dr. Lanier has numerous patents and over 50 peer-reviewed publications reflecting more than 25 years of experience working on the discovery and development of antivirals and anticancer drugs. He has focused much of his career on understanding the activity, mechanisms of action, and resistance profiles of nucleoside analogs. His undergraduate degree was in Biology from New College in Sarasota, FL and his PhD was in Cellular and Structural Biology from the University of Texas Health Science Center in San Antonio, TX. He is currently Chief Scientific Officer at Chimerix.
This post was written by tbe_admin